Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC

PDT Partners LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 352,498 shares of the biopharmaceutical company's stock after purchasing an additional 99,539 shares during the period. PDT Partners LLC owned about 0.12% of Amicus Therapeutics worth $3,321,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Amicus Therapeutics in the 3rd quarter worth $107,000. Diversified Trust Co increased its position in Amicus Therapeutics by 9.7% during the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company's stock worth $770,000 after purchasing an additional 7,257 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $123,000. Avanza Fonder AB purchased a new stake in Amicus Therapeutics in the fourth quarter valued at $157,000. Finally, KBC Group NV boosted its stake in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD traded down $0.01 during midday trading on Friday, reaching $6.67. The stock had a trading volume of 6,371,892 shares, compared to its average volume of 2,692,364. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a market cap of $2.05 billion, a P/E ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79. The firm has a fifty day simple moving average of $7.95 and a two-hundred day simple moving average of $9.29. Amicus Therapeutics, Inc. has a 12-month low of $6.20 and a 12-month high of $12.65.

Wall Street Analysts Forecast Growth

FOLD has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. UBS Group upped their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.